Navigation Links
Difficult-to-Treat Patient Populations Respond Positively to Hepatitis C Treatment
Date:10/28/2009

ALEXANDRIA, Va., and BOSTON, Oct. 28 /PRNewswire/ -- The final results of the PROVE3 study will be presented at this year's annual meeting of the American Association for the Study of Liver Diseases. This phase 2 study was of telaprevir compared to a combination therapy of peginterferon alfa-2a and ribavirin. It intended to measure the 6 month and also 1-year durability of sustained viral response in genotype 1 patients with HCV who failed prior treatment with pegylated interferon and ribavirin.

According to John McHutchison, MD, principal investigator for this study, "This was the first large scale study performed in nonresponders to our current standard of care, which evaluated retreating these patients with the addition of an HCV-specific protease inhibitor. Its importance is, therefore, the proof of principle that adding this potent direct anti-viral allowed us to cure approximately 50 percent of this patient population who have failed therapy and for which no other options currently exists."

The study included 453 patients, and the SVR rates in all treatment groups who received the telaprevir-based therapy were significantly higher than those who received peginterferon alfa-2a and ribavirin. All patients who received telaprevir and achieved virologic response maintained it for 48 weeks after the end of the treatment.

The drug in this nonresponder setting is currently undergoing phase 3 large-scale registration trials to confirm and further elucidate the findings of this current phase 2 study. "To sit across the desk from our hepatitis C patients and tell those that have not responded that with this retreatment strategy they have a 50 percent chance of being cured will be a huge message for patients and providers if confirmed in larger phase 3 clinical trials," concluded Dr. McHutchison.

Abstract title:

PROVE3 final results and 1-year durability of SVR with Telaprevir-based regimen in hepati
'/>"/>

SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
2. Patients who Participated in Pleio GoodStart(TM) Refilled 30% Sooner and 40% More, Averaging 2 Additional Rx Refills per Patient
3. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
4. Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study
5. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
6. Long-Term Data Updates Show Further Extensions of Survival and Delays in Recurrence in Brain Cancer Patients Who Received DCVax(R)-Brain
7. Patients Receiving High Radiation at Cedars Sinai File Class Action Lawsuit
8. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
9. Patients Taking VIMOVO(TM) Showed a Decrease in Incidence of NSAID-Associated Ulcers
10. ULORIC(R) (febuxostat) Demonstrated Efficacy for Management of Hyperuricemia in Patients with Gout
11. EPIX Pharmaceuticals Announces FDA Approval of a Physician-Sponsored IND for Fourth 6-month Open Label Extension of PRX-03140 for Alzheimers Disease Patient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013  Echo Therapeutics, ... developing its needle-free Symphony ® CGM System ... today announced the closing of a previously announced ... common stock and the full exercise of the ... at a price to the public of $2.70 ...
(Date:6/19/2013)... , June 19, 2013 Pharmacyclics, Inc. (the ... The New England Journal of Medicine ( ... study evaluating the investigational oral Bruton,s tyrosine kinase (BTK) ... (CLL) or small lymphocytic lymphoma (SLL). Ibrutinib was shown ... CLL or SLL, even in patients who were at ...
(Date:6/19/2013)... BELLEVUE, Wash. , June 19, 2013 ... Provisioning version 4.0, a solution designed to ... to applications and data while supporting their ... release of Provisioning represents a milestone in ... governance and analytics capabilities for health systems. ...
Breaking Medicine Technology:Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter 2Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 2Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 3Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 4Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 5Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine 6Caradigm Provisioning Helps Healthcare Organizations Improve Clinical Efficiency, Manage Risk 2Caradigm Provisioning Helps Healthcare Organizations Improve Clinical Efficiency, Manage Risk 3
... , ATLANTA , March 16 ... developing and delivering unique extracellular matrix (ECM) biomaterial devices ... cardiovascular tissue, announced today that investigators from the ... and CorMatrix Cardiovascular, Inc. demonstrated that an injectable ...
... March 16 AstraZeneca (NYSE: AZN ) ... (A Study of PLAT elet Inhibition and Patient ... patients with acute coronary syndromes (ACS) who took the investigational ... heart bypass surgery (coronary artery bypass graft, CABG) compared to ...
Cached Medicine Technology:CorMatrix Announces Publication of Pre-Clinical Data in Journal of American College of Cardiology (JACC) Demonstrating the Role of CorMatrix ECM(TM) Technology in Remodeling Cardiac Tissue 2CorMatrix Announces Publication of Pre-Clinical Data in Journal of American College of Cardiology (JACC) Demonstrating the Role of CorMatrix ECM(TM) Technology in Remodeling Cardiac Tissue 3CorMatrix Announces Publication of Pre-Clinical Data in Journal of American College of Cardiology (JACC) Demonstrating the Role of CorMatrix ECM(TM) Technology in Remodeling Cardiac Tissue 4CorMatrix Announces Publication of Pre-Clinical Data in Journal of American College of Cardiology (JACC) Demonstrating the Role of CorMatrix ECM(TM) Technology in Remodeling Cardiac Tissue 5CorMatrix Announces Publication of Pre-Clinical Data in Journal of American College of Cardiology (JACC) Demonstrating the Role of CorMatrix ECM(TM) Technology in Remodeling Cardiac Tissue 6New PLATO Sub-Analysis of CABG Patients Presented at ACC 2New PLATO Sub-Analysis of CABG Patients Presented at ACC 3New PLATO Sub-Analysis of CABG Patients Presented at ACC 4New PLATO Sub-Analysis of CABG Patients Presented at ACC 5New PLATO Sub-Analysis of CABG Patients Presented at ACC 6New PLATO Sub-Analysis of CABG Patients Presented at ACC 7
(Date:6/20/2013)... Businesses which are failing to be savvy ... up in the tidal wave of competition, warns Australia's leading ... Marketing: 50 Tips Collected from the Top Blogs is ... is to listen to the social media pros. This is ... media since its onset and they, more than most PR ...
(Date:6/20/2013)... June 20, 2013 Millions of Britons ... serious medical conditions because they do not brush their ... and Elgydium toothpaste. , Seven million Britons do not ... hours between brushes, latest data from the British Dental ... people polled by the BDHF also admitted that they ...
(Date:6/20/2013)... HIPAA One aims to ... a HIPAA Security Risk Analysis using the simplest workflow ... the reach of all the HIPAA programs by serving ... Officers, security professionals, and members of the Healthcare interested ... and procedures. The new Web site features expanded ...
(Date:6/19/2013)... CA (PRWEB) June 19, 2013 Paleo Burn ... thousands of people finally sculpt the body they desire with ... other fat loss programs and health food products, Ken Smith ... and finally give consumers an easy, automatic, and permanent solution ... all the details . , After a quick review of ...
(Date:6/19/2013)... A man returning from war is not likely to ... his debut book titled RED DANCER JOURNEY, author Rafael Fraguada pens ... home, looking for the right place and people to mend his ... from the Vietnam War, returns to New York City, he meets ... Wings, a wealthy acquaintance from a tiny Midwest college they both ...
Breaking Medicine News(10 mins):Health News:Social Media Marketing: Casey Gollan's Round-up of Tips from the Top Blogs 2Health News:Social Media Marketing: Casey Gollan's Round-up of Tips from the Top Blogs 3Health News:Millions Are Risking Gum Disease, Warn Eludril And Elgydium 2Health News:Millions Are Risking Gum Disease, Warn Eludril And Elgydium 3Health News:Modern Compliance Solutions Launches a New Web Site Promoting the Industry-Proven, Web-Based HIPAA One Security Solution 2Health News:Paleo Burn Review Released by TotalWellnessCleanse.net 2Health News:Rafael Fragauda’s New Book Underlines Post Traumatic Stress Disorder 2
... surgery reduces potentially serious kidney complications, according to a ... Journal of the American Society Nephrology (JASN). ... are performed around the world. Unfortunately, many patients who ... often due to decreased blood flow to the kidneys ...
... 14 (HealthDay News) -- Trying to make the best of the ... with losing their jobs, a new United Kingdom study finds. ... their job loss were able to see the event as a ... and study. They also took a contemplative view of their ...
... has found that the majority of individuals with substance ... found that opioid users, in particular, showed a decline ... These findings appear online in the Journal of ... and internal medicine faculty from Boston University investigated the ...
... , THURSDAY, April 14 (HealthDay News) -- The best ... new study suggests. Supportive reactions by managers and ... to positive changes in the workplace, while chastising or ... chair of the human resource management department at Temple ...
... --- Battling an illness, lack of sleep and strange ... sorts. For seniors, hospitalizations actually may cause ... according to a new Northwestern Medicine study. ... the hospital stay, the study found. But immediately following ...
... circadian system that controls normal sleep patterns is regulated ... according to a study published online on April 14th ... Neuroscientists from Tufts University School of Medicine found that ... to altered daily rhythms, an indication that these star-shaped ...
Cached Medicine News:Health News:Statins may protect against kidney complications following elective surgery 2Health News:Good Attitude Critical When Coping With Layoff Trauma 2Health News:Compassion, Not Punishment, Helps Diffuse Workplace Anger: Study 2Health News:Temporary memory loss strikes hospitalized seniors 2Health News:Rising star of brain found to regulate circadian rhythms 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: